Business Today
Loading...

Biological E to begin Phase III clinical trial of COVID-19 vaccine candidate

The vaccination schedule for Biological E's COVID-19 vaccine candidate consistes of two doses for each study participant, administered via intramuscular injection 28 days apart

twitter-logoJoe C Mathew | April 24, 2021 | Updated 21:08 IST
Biological E to begin Phase III clinical trial of COVID-19 vaccine candidate

Hyderabad-based vaccine maker Biological E (BE) will start the final Phase III stage of clinical trials of its potential COVID-19 vaccine candidate soon. The company has successfully completed the Phase I and II clinical trials of its COVID-19 sub-unit vaccine candidate in India. The regulatory approval to start the Phase III clinical trial is also in place, the company said.

"We are delighted with the success of the Phase I/II clinical trials of our COVID-19 vaccine candidate. The results of these clinical trials are very positive and promising. We believe that our vaccine candidate will become another effective global COVID-19 vaccine as we move forward into Phase III clinical trials," Mahima Datla, Managing Director, BE, said.

ALSO READ: Fourth COVID-19 vaccine soon; Biological E's shot likely to hit markets in August

The company's vaccine candidate includes an antigen developed by Texas Children's Hospital Center for Vaccine Development and in-licensed from BCM Ventures, Baylor College of Medicine's integrated commercialisation team, along with Dynavax Technologies Corporation's advanced adjuvant CpG 1018. The Coalition for Epidemic Preparedness Innovations (CEPI) and the Biotechnology Industry Research Assistance Council (BIRAC) have provided support for the Phase I/II clinical trials and also for the upcoming Phase III trial of this vaccine candidate.

BE started the Phase I/II clinical trial of its COVID-19 vaccine candidate in the second week of November 2020. The Phase I/II clinical trial evaluated the safety and immunogenicity of the vaccine candidate consisting of the receptor binding domain of the spike protein of SARS-CoV-2 at three-dose level adjuvanted with CpG 1018 plus alum, in about 360 healthy subjects in the age range of 18 to 65 years. The vaccination schedule consisted of two doses for each study participant, administered via intramuscular injection 28 days apart.

ALSO READ: COVID-19: Pfizer to supply coronavirus vaccine at 'not-for-profit' rate to Centre

"Having our Texas Children's and Baylor vaccine construct advance into phase III clinical studies in India and globally highlights the importance of advancing traditional protein-based vaccine platforms, which now brings added hope for a people's vaccine to be scaled and deployed in low- and middle-income settings," said Dr Maria Elena Bottazzi, associate dean of the National School of Tropical Medicine at Baylor College of Medicine and co-director of Texas Children's Hospital Center for Vaccine Development.

"This vaccine could one day soon fill urgently needed gaps and vaccine supply shortages in Africa, Latin America, and in low-income Asian countries.  It's so exciting to partner with BE helping India to provide a vaccine to halt the COVID-19 pandemic globally," said Dr Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor and co-director of Texas Children's Hospital Center for Vaccine Development.

ALSO READ: Johnson & Johnson COVID-19 vaccine likely to be imported by July

The Phase III clinical study to be conducted in 15 sites across India will evaluate the Immunogenicity and Safety of Biological E's COVID-19 vaccine for protection against COVID-19 disease in about 1,268 healthy subjects in the age range of 18 to 80 years. It is intended to be part of a larger global Phase III study.

  • Print
  • COMMENT
BT-Story-Page-B.gif
A    A   A
close